EGFR and in situ carcinoma: A locoregional pilot study to evaluate the feasibility, tolerability, and efficacy of 213Bi-anti-EGFR mAb treatment in patients with bacillus Calmette-Guerin (BCG) refractory carcinoma in situ (CIS) was performed [78].